Search results for "Etidronic Acid"

showing 3 items of 3 documents

Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.

2011

The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC). In a group of 51 elderly women (aged 76.4 ± 5.0 years) considered for adjuvant aromatase inhibitors for EBC, 24 patients with T-scores ≥ -2 and no prevalent fractures received anastrozole 1 mg/day (group A), and 27 patients with T-scores < -2, or with T-scores ≥ -2 and prevalent fractures (group B), received anastrozole (1 mg/day) plus risedronate (35 mg/week). Both groups received supplementation with 1 g calcium carbonate and 800 IU vitamin D per day. Differen…

Endocrinology Diabetes and MetabolismOsteoporosisSeverity of Illness IndexCohort StudiesEndocrinologyBone DensityOrthopedics and Sports MedicineVitamin DAromataseOsteoporosis PostmenopausalAged 80 and overBone Density Conservation AgentsbiologyAromatase InhibitorsEtidronic AcidGeneral MedicineCombined Modality Therapymedicine.anatomical_structureFemaleRisedronic Acidmedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyAntineoplastic Agents HormonalUrologyAnastrozoleBreast NeoplasmsAnastrozoleCalcium CarbonateNitrilesmedicineVitamin D and neurologyHumansBone ResorptionAgedNeoplasm StagingFemoral neckTrochanterbusiness.industryBone fractureTriazolesmedicine.diseaseSurgeryEarly breast cancer Anastrozole Osteoporosis Vertebral fractures ElderlyDietary SupplementsOrthopedic surgerybiology.proteinbusinessOsteoporotic FracturesFollow-Up Studies
researchProduct

Inorganic Polyphosphate in Human Osteoblast-like Cells

1998

Significant amounts of inorganic polyphosphates and of polyphosphate-degrading exopolyphosphatase activity were detected in human mandibular-derived osteoblast-like cells. The amount of both soluble and insoluble long-chain polyphosphate in unstimulated osteoblast-like cells was higher than in human gingival cells, erythrocytes, peripheral blood mononuclear cells, and human blood plasma. The cellular content of polyphosphate in osteoblast-like cells strongly decreased after a combined treatment of the cells with the stimulators of osteoblast proliferation and differentiation, dexamethasone, beta-glycerophosphate, epidermal growth factor, and ascorbic acid. The amount of soluble long-chain p…

HL60Endocrinology Diabetes and MetabolismHL-60 CellsMandibleBiologyDexamethasonechemistry.chemical_compoundCalcitriolPolyphosphatesEpidermal growth factormedicineAnimalsHumansOrthopedics and Sports MedicinePyrophosphatasesCells CulturedExopolyphosphataseOsteoblastsDiphosphonatesEpidermal Growth FactorPolyphosphateCell DifferentiationEtidronic AcidOsteoblastAlkaline PhosphataseAscorbic acidAcid Anhydride HydrolasesRatsInorganic Pyrophosphatasemedicine.anatomical_structureSolubilitychemistryBiochemistryCell cultureGlycerophosphatesAlkaline phosphataseCell DivisionJournal of Bone and Mineral Research
researchProduct

Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study

2006

None of the available osteoporosis therapies have been shown to completely abolish the risk of fractures. In clinical practice, the outcome may be even poorer. In 880 patients prescribed with antiresorptives (alendronate, risedronate, and raloxifene) for >1 year, a fragility fracture was recorded in 8.9%/year of them. This incidence is considerably higher than that observed in randomized clinical trials, and it was significantly related to poor compliance and lack of supplementation with calcium and vitamin D. Introduction: Osteoporotic fracture is one of the most important public health concerns among the elderly. Currently available therapies have been shown to significantly decrease the …

medicine.medical_specialtyFracture riskEndocrinology Diabetes and MetabolismOsteoporosisIncidence; FRACTURETreatment resistancelaw.inventionCalcium and vitamin D intake Fracture risk Osteoporosis Treatment compliance Treatment resistancecalcium and vitamin d intake; fracture risk; osteoporosis; treatment compliance; treatment resistanceFractures BoneRandomized controlled trialRisk FactorslawInternal medicineCalcium and vitamin D intakemedicineVitamin D and neurologyHumansOrthopedics and Sports MedicineRaloxifeneVitamin DAgedRetrospective StudiesAlendronateBone Density Conservation Agentsbusiness.industryIncidenceIncidence (epidemiology)Etidronic AcidRetrospective cohort studyMiddle Agedmedicine.diseaseCalcium and vitamin D intake Fracture incidence Fracture risk Osteoporosis Treatment compliance Treatment resistanceFRACTUREFracture incidenceSurgeryItalyRaloxifene HydrochlorideRisedronic acidOsteoporosisFemaleObservational studyTreatment compliancebusinessRisedronic Acidmedicine.drug
researchProduct